Experienced in Ewing Sarcoma

Dr. Trisha Wise

Hematology | Oncology
University Of Cincinnati Physicians Company LLC
3188 Bellevue Ave, 
Cincinnati, OH 
Clinical Trials:Currently Recruiting for 2 Trials
Experienced in Ewing Sarcoma
University Of Cincinnati Physicians Company LLC
3188 Bellevue Ave, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Trisha Wise is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Wise is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Laryngeal Cancer, Throat Cancer, Oral Squamous Cell Carcinoma, and Gastrostomy.

Her clinical research consists of co-authoring 108 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Hospital Affiliations
West Chester Hospital
University Of Cincinnati Medical Center, LLC
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

UNIVERSITY OF CINCINNATI PHYSICIANS COMPANY LLC
3188 Bellevue Ave, Cincinnati, OH 45219

Additional Areas of Focus

Dr. Wise has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: September 19, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination With Standard Therapy in Recurrent High Grade Gliomas
A Phase 0/1 Pharmacokinetic and Pharmacodynamics and Safety and Tolerability Study of Letrozole in Combination With Standard Therapy in Recurrent High Grade Gliomas
Enrollment Status: Recruiting
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drug: Letrozole Oral Tablet
Study Phase: Early Phase 1
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
A Phase 1 Study Investigating AGEN1777 as a Single-Agent and in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Phase: Phase 1
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Cabozantinib, Vandetanib
Study Phase: Phase 3
Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2024
Intervention Type: Radiation, Procedure, Drug
Study Drugs: Pembrolizumab, Cisplatin
Study Phase: Phase 2
An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
An Open-label, Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin to Harness the Natural Killer Cytotoxic Response in Metastatic Head and Neck Cancer Patients
A Phase 2 Feasibility Study Combining Pembrolizumab and Metformin to Harness the Natural Killer Cytotoxic Response in Metastatic Head and Neck Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drugs: Metformin, Pembrolizumab
Study Phase: Phase 2
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: July 25, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors
A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: April 24, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy
A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2024
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Terminated
Publish Date: April 03, 2023
Intervention Type: Drug
Study Drugs: CDX-3379, Cetuximab
Study Phase: Phase 2
View 10 Less Clinical Trials

101 Total Publications

Potassium channels mediate the inhibitory effect of exosomes on anti-tumor immunity in head and neck cancer.
Potassium channels mediate the inhibitory effect of exosomes on anti-tumor immunity in head and neck cancer.
Journal: bioRxiv : the preprint server for biology
Published: August 06, 2025
Similar Doctors
Experienced in Ewing Sarcoma
Dr. Raehannah J. Jamshidi
Hematology | Oncology | Pediatrics
Experienced in Ewing Sarcoma
Dr. Raehannah J. Jamshidi
Hematology | Oncology | Pediatrics

Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (1.1 miles away)
513-636-4200
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Raehannah Jamshidi is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Jamshidi is rated as an Experienced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Ewing Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Bone Tumor, and Neuroblastoma. Dr. Jamshidi is currently accepting new patients.

Experienced in Ewing Sarcoma
Dr. Priya G. Jain
Oncology | Hematology Oncology | Hematology
Experienced in Ewing Sarcoma
Dr. Priya G. Jain
Oncology | Hematology Oncology | Hematology

Kettering Independent Medical Group Inc

4441 Far Hills Ave, 
Kettering, OH 
 (42.6 miles away)
937-298-7751
Languages Spoken:
English, Tamil
See accepted insurances
Accepting New Patients

Priya Jain is an Oncologist and a Hematologist Oncology provider in Kettering, Ohio. Dr. Jain is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Paget Disease of the Breast, Familial Colorectal Cancer, Colorectal Cancer, and Breast Cancer. Dr. Jain is currently accepting new patients.

Experienced in Ewing Sarcoma
Dr. Brian Mannion
Hematology | Oncology
Experienced in Ewing Sarcoma
Dr. Brian Mannion
Hematology | Oncology

Christ Hospital Medical Specialists Ii, LLC

1955 Dixie Hwy, Suite G, 
Fort Wright, KY 
 (5.3 miles away)
859-331-3304
Languages Spoken:
English
See accepted insurances

Brian Mannion is a Hematologist and an Oncologist in Fort Wright, Kentucky. Dr. Mannion is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Pleuropulmonary Blastoma, Paget Disease of the Breast, Lung Cancer, and Angiosarcoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Wise's expertise for a condition
ConditionClose
View All 35 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile